Introduction:
German contract manufacturing organization (CDMO) Wacker Biotech has opened a new production facility for RNA vaccines and therapeutics, expanding its expertise in the field of RNA active ingredients. The facility, which cost €100m to construct, will create 100 new jobs and has the capacity to produce over 200 million vaccine doses annually. Wacker Biotech was awarded a tender by the German government in 2022 to manufacture RNA vaccines for pandemic preparedness.
- Wacker Biotech has opened a new production facility for RNA vaccines and therapeutics.
- The facility has an annual production capacity of over 200 million vaccine doses.
- The facility was constructed at a cost of €100m and will create 100 new jobs.
- Wacker Biotech was awarded a tender by the German government in 2022 for pandemic preparedness.
- The facility will also help meet the growing demand for RNA medications, such as RNA cancer vaccines, siRNA, and RNA-based gene therapies.
Conclusion:
Wacker Biotech’s new production facility for RNA vaccines and therapeutics will help meet the demand for RNA medications and contribute to Germany’s pharma strategy. The facility’s annual production capacity of over 200 million vaccine doses will be vital in pandemic preparedness and future RNA-based drug development.
